(Reuters) – A panel of U.S. Food and Drug Administration advisers on Wednesday recommended approval for GSK Plc’s drug to treat anemia caused by chronic kidney disease (CKD) for a smaller-than-expected patient population.
The panel voted in favor of the drug only for patients on dialysis, although GSK was aiming for approval for a broader CKD population, regardless of dialysis status.
(Reporting by Khushi Mandowara and Leroy Leo in Bengaluru; additional reporting by Natalie Grover in London; Editing by Shinjini Ganguli)
